[go: up one dir, main page]

WO1998019670A3 - Combination therapy of hepatitis C infections - Google Patents

Combination therapy of hepatitis C infections Download PDF

Info

Publication number
WO1998019670A3
WO1998019670A3 PCT/US1997/019763 US9719763W WO9819670A3 WO 1998019670 A3 WO1998019670 A3 WO 1998019670A3 US 9719763 W US9719763 W US 9719763W WO 9819670 A3 WO9819670 A3 WO 9819670A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
hepatitis
infections
combination therapy
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/019763
Other languages
French (fr)
Other versions
WO1998019670A2 (en
Inventor
Thomas Najarian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU51579/98A priority Critical patent/AU5157998A/en
Publication of WO1998019670A2 publication Critical patent/WO1998019670A2/en
Publication of WO1998019670A3 publication Critical patent/WO1998019670A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compositions useful for treatment of hepatitis C infection are disclosed. In general, the compositions comprise a composition comprising at least two compounds selected from the group consisting of a nucleoside analog, a quinolone antibiotic, and an amantadine anti-viral agent. The compositions or drug combinations can optionally include an interferon, such as interferon α. Pharmaceutical compositions and kits including the compositions of the invention are also disclosed.
PCT/US1997/019763 1996-11-01 1997-10-31 Combination therapy of hepatitis c infections Ceased WO1998019670A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51579/98A AU5157998A (en) 1996-11-01 1997-10-31 Methods and compositions for treatment of hepatitis c infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74311496A 1996-11-01 1996-11-01
US08/743,114 1996-11-01
US87066297A 1997-06-06 1997-06-06
US08/870,662 1997-06-06

Publications (2)

Publication Number Publication Date
WO1998019670A2 WO1998019670A2 (en) 1998-05-14
WO1998019670A3 true WO1998019670A3 (en) 1998-08-13

Family

ID=27114104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019763 Ceased WO1998019670A2 (en) 1996-11-01 1997-10-31 Combination therapy of hepatitis c infections

Country Status (2)

Country Link
AU (1) AU5157998A (en)
WO (1) WO1998019670A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
CN1276730A (en) * 1997-09-18 2000-12-13 霍夫曼-拉罗奇有限公司 Use of IFN-alpha and amantadine for treatment of chronic hepatitis C
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases
CA2306039A1 (en) * 1999-04-19 2000-10-19 Schering Corporation Hcv combination therapy
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
DE10001729A1 (en) * 2000-01-17 2001-07-26 Morphochem Ag Use of special compounds for the prophylaxis and therapy of hepatitis C.
EP1325324A4 (en) * 2000-08-02 2004-11-10 Ortho Mcneil Pharm Inc IMPROVED ANTIVIRUS AND ANTITUMOR CHEMOTHERAPY BY ADMINISTRATION OF ERYTHROPOEITIN
JP2005504087A (en) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
GB0215617D0 (en) * 2002-07-08 2002-08-14 Univ Leeds Use of hepatitis C virus (HCV) p7 protein
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (en) 2011-10-21 2015-03-19 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
WO2017114812A1 (en) * 2015-12-29 2017-07-06 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an interferon
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707855A2 (en) * 1995-05-19 1996-04-24 Schering Corporation Combination therapy for chronic hepatitis C infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707855A2 (en) * 1995-05-19 1996-04-24 Schering Corporation Combination therapy for chronic hepatitis C infection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRACONIER J H ET AL: "COMBINED ALPHA-INTERFERON AND RIBAVIRIN TREATMENT IN CHRONIC HEPATITIS C: A PILOT STUDY", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, vol. 27, no. 4, 1995, pages 325 - 329, XP000600916 *
BRILLANTI S ET AL: "A PILOT STUDY OF COMBINATION THERAPY WITH RIBAVIRIN PLUS INTERFERON ALFA FOR INTERFERON ALFA-RESISTANT CHRONIC HEPATITIS C", GASTROENTEROLOGY, vol. 107, no. 3, September 1994 (1994-09-01), pages 812 - 817, XP000600924 *
KOMATSU M ET AL: "Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration.", CANADIAN JOURNAL OF GASTROENTEROLOGY, vol. 11, no. 6, September 1997 (1997-09-01), pages 507 - 511, XP002057490 *
SMITH J P: "Treatment of chronic hepatitis C with amantadine -hydrochloride.", 96TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION AND THE DIGESTIVE DISEASE WEEK, SAN FRANCISCO, CALIFORNIA, USA, MAY 19-22, 1996. GASTROENTEROLOGY 110 (4 SUPPL.). 1996. A1330. ISSN: 0016-5085, XP002057489 *
SMITH J P: "Treatment of chronic hepatitis C with amantadine.", DIGESTIVE DISEASES AND SCIENCES, vol. 42, no. 8, August 1997 (1997-08-01), USA, pages 1681 - 1687, XP002057488 *
TSUTSUMI, MIKIHIRO ET AL: "Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: A pilot study", J. GASTROENTEROL. HEPATOL. (1996), 11(11), 1006-1011 CODEN: JGHEEO;ISSN: 0815-9319, XP002057491 *

Also Published As

Publication number Publication date
WO1998019670A2 (en) 1998-05-14
AU5157998A (en) 1998-05-29

Similar Documents

Publication Publication Date Title
WO1998019670A3 (en) Combination therapy of hepatitis C infections
AU2959595A (en) Camptothecin drug combinations and medicaments with reduced side effects
AUPP437698A0 (en) Methods for treatment of coronary, carotid and other vascular disease
FR2757521B1 (en) NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1128832A4 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
FR2757522B1 (en) CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PL344223A1 (en) Compositions for the treatment of hiv and other viral infections
HUP0002662A3 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
ES2181744T3 (en) HYDRAPTS OF PACLITAXEL CRISTALINOS.
DK0825186T3 (en) 2-aminobenzazepine derivatives and their use in the treatment of immunosuppression
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
AUPP589598A0 (en) Novel peptides
EP0932613A4 (en) BLOCKING OF AGGRESSIN EXPRESSION IN S. AUREUS
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
CA2141056A1 (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
IL111338A0 (en) Pharmaceutical or veterinary compositions comprising flavin derivatives for the treatment of viral infections and their preparation
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
CA2330424A1 (en) Improved method for eradication of helicobacter pylori
AU4568400A (en) Sphingomyelinase inhibitor
FI965114A7 (en) Pharmaceutical composition for the prevention and (or) treatment of viral infections and optionally inflammations, and method of treating them
HUP0003409A3 (en) Use of macrolide antibiotics for the prepartion of pharmaceutical compositions treating or preventing coccidiosis
WO2001051603A3 (en) Pharmaceutical composition and method of using the same
PT1181300E (en) DERIVATIVES 6-O-CARBAMATE OF CETOLID

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA